BRAF Mutation Testing and Metastatic Colorectal Cancer in the Community Setting: Is There an Urgent Need for More Education?

作者： Timothy J. Price , Carol Beeke , Amanda Rose Townsend , Louisa Lo , Roy Amitesh

关键词: Fluorouracil 、 Capecitabine 、 Genetic testing 、 Young adult 、 Mutation (genetic algorithm) 、 Colorectal cancer 、 Oncology 、 Pharmacotherapy 、 Medicine 、 Bevacizumab 、 Internal medicine

摘要: Background Patients with metastatic colorectal cancer (mCRC) BRAF mutation (BRAF MT) generally have a poorer prognosis. MT may also implications for treatment strategy. Despite this, inclusion of in routine molecular testing varies. Here we report the frequency reporting South Australian (SA) mCRC registry reflecting community practice, together survival outcomes based on status.

springer.com LINK 下载加速

sci-hub.se PDF 下载加速

参考文章(38)

T T Seppälä, J P Böhm, M Friman, L Lahtinen, V M J Väyrynen, T K E Liipo, A P Ristimäki, M V J Kairaluoma, I H Kellokumpu, T H I Kuopio, J-P Mecklin, Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer. British Journal of Cancer. ,vol. 112, pp. 1966- 1975 ,(2015) , 10.1038/BJC.2015.160

Andrew Rowland, Mafalda M Dias, Michael D Wiese, Ganessan Kichenadasse, Ross A McKinnon, Christos S Karapetis, Michael J Sorich, Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. British Journal of Cancer. ,vol. 112, pp. 1888- 1894 ,(2015) , 10.1038/BJC.2015.325

Wei Qi Li, Kazuyuki Kawakami, Andrew Ruszkiewicz, Graeme Bennett, James Moore, Barry Iacopetta, BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status Molecular Cancer. ,vol. 5, pp. 2- 2 ,(2006) , 10.1186/1476-4598-5-2

Eu Ling Neo, Carol Beeke, Timothy Price, Guy Maddern, Chris Karapetis, Colin Luke, David Roder, Robert Padbury, South Australian clinical registry for metastatic colorectal cancer Anz Journal of Surgery. ,vol. 81, pp. 352- 357 ,(2011) , 10.1111/J.1445-2197.2010.05589.X

David M. Hyman, Igor Puzanov, Vivek Subbiah, Jason E. Faris, Ian Chau, Jean-Yves Blay, Jürgen Wolf, Noopur S. Raje, Eli L. Diamond, Antoine Hollebecque, Radj Gervais, Maria Elena Elez-Fernandez, Antoine Italiano, Ralf-Dieter Hofheinz, Manuel Hidalgo, Emily Chan, Martin Schuler, Susan Frances Lasserre, Martina Makrutzki, Florin Sirzen, Maria Luisa Veronese, Josep Tabernero, José Baselga, Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations The New England Journal of Medicine. ,vol. 373, pp. 726- 736 ,(2015) , 10.1056/NEJMOA1502309

E. Van Cutsem, C. Atreya, T. André, J. Bendell, J. Schellens, M. Gordon, A. McRee, T. Yoshino, K. Muro, P. ODwyer, J. Tabernero, G. Middleton, M. Ducreux, R. van Geel, R. Sidhu, J. Greger, F. Rangwala, Y. Liu, Y. Wu, B. Mookerjee, R. Corcoran, LBA-07Updated Results of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC) Annals of Oncology. ,vol. 26, ,(2015) , 10.1093/ANNONC/MDV262.07

C. Cremolini, M. Di Bartolomeo, A. Amatu, C. Antoniotti, R. Moretto, R. Berenato, F. Perrone, E. Tamborini, G. Aprile, S. Lonardi, A. Sartore-Bianchi, G. Fontanini, M. Milione, C. Lauricella, S. Siena, A. Falcone, F. de Braud, F. Loupakis, F. Pietrantonio, BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis Annals of Oncology. ,vol. 26, pp. 2092- 2097 ,(2015) , 10.1093/ANNONC/MDV290

Feriyl Bhaijee, Thomas Huebner, Ralph H. Hruban, Laura D. Wood, Nathan Cuka, Drew M. Pardoll, Nickolas Papadopoulos, Kenneth W. Kinzler, Shibin Zhou, Toby C. Cornish, Janis M. Taube, Robert A. Anders, James R. Eshleman, Bert Vogelstein, Luis A. Diaz, Dung T. Le, Jennifer N. Uram, Hao Wang, Bjarne R. Bartlett, Holly Kemberling, Aleksandra D. Eyring, Andrew D. Skora, Brandon S. Luber, Nilofer S. Azad, Dan Laheru, Barbara Biedrzycki, Ross C. Donehower, Atif Zaheer, George A. Fisher, Todd S. Crocenzi, James J. Lee, Steven M. Duffy, Richard M. Goldberg, Albert de la Chapelle, Minori Koshiji, PD-1 Blockade in Tumors with Mismatch-Repair Deficiency The New England Journal of Medicine. ,vol. 372, pp. 2509- 2520 ,(2015) , 10.1056/NEJMOA1500596

Van Morris, Michael J. Overman, Zhi-Qin Jiang, Christopher Garrett, Shweta Agarwal, Cathy Eng, Bryan Kee, David Fogelman, Arvind Dasari, Robert Wolff, Dipen Maru, Scott Kopetz, Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clinical Colorectal Cancer. ,vol. 13, pp. 164- 171 ,(2014) , 10.1016/J.CLCC.2014.06.001

10.

Filippo Pietrantonio, Fausto Petrelli, Andrea Coinu, Maria Di Bartolomeo, Karen Borgonovo, Claudia Maggi, Mary Cabiddu, Roberto Iacovelli, Ilaria Bossi, Veronica Lonati, Mara Ghilardi, Filippo de Braud, Sandro Barni, Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis European Journal of Cancer. ,vol. 51, pp. 587- 594 ,(2015) , 10.1016/J.EJCA.2015.01.054

BRAF Mutation Testing and Metastatic Colorectal Cancer in the Community Setting: Is There an Urgent Need for More Education?

来源期刊

我的账户

BRAF Mutation Testing and Metastatic Colorectal Cancer in the Community Setting: Is There an Urgent Need for More Education?

来源期刊

相似文章 3

Prevalence of BRAF gene mutation in samples of primary and metastatic colorectal cancer: A meta‐analysis

Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta‐analysis

Treatment and outcomes of metastatic colorectal cancer patients in public and private hospitals: Results from the South Australian Metastatic Colorectal Cancer Registry.

我的账户